A series of reports on the 8th China Hospital Pharmaceutical Policy Forum i-introduction to the 2017 edition of Medicare drug catalog

Source: China pharmaceutical innovation promotion association July 24, 2017 Huang Xinyu, director of the Management Office of the medical insurance Department of the Ministry of human resources and social security, made a report on the theme of "Introduction to the 2017 version of the medical insurance drug catalog" at the 8th hospital pharmacy forum He focused on three aspects - "basic situation, main considerations and future prospects" to adjust the principles of the new version of the medical insurance drug catalog, compare the improvements of the previous versions of the catalog and the trend of the future medical insurance catalog management policies Understand reading Huang Xinyu, director of the Management Office of the medical insurance Department of the Ministry of human resources and social security, collected 2535 drugs from western medicine and Chinese patent medicine in 2017, an increase of 15.4% compared with that in 2009 Compared with the previous versions, the new version of the medical insurance drug catalog shows the following changes: with the change of drug use habits and the continuous improvement of financing level, the new version of the medical insurance drug catalog covers more insurance types, including urban workers, urban and rural residents, work-related injury and childbirth; the drug use level is gradually improved, the new version of the catalog is included in the scope of drugs, and the treatment of major diseases is expanded Therapeutic drugs, rare disease drugs and innovative drugs have been paid attention to, most of the first class innovative drugs have been included in the scope of basic medical insurance; the use management has been gradually scientific, more detailed and perfect, the management concept has been in line with the international standards as far as possible, and reflects the characteristics of medical insurance management; in terms of the directory structure, the number of Chinese and Western medicine varieties is the same, and appropriate to Chinese medicine and ethnic medicine The 2017 edition of the medical insurance drug catalog adjustment mainly considers several principles - basic protection, focus, strong management and innovation promotion In the procedure, the expert vote system is still used, and the evaluation experts are composed of clinicians, pharmaceutical experts, economic experts, management experts, etc Basic security - mainly considering the level of economic development, medical technology, medical insurance management ability and social affordability Focusing on the key points - the drugs included must be the varieties that are necessary for clinical diagnosis and treatment, focus on medical insurance, the urgent expectation of the masses, and conform to the national policies Strengthen management - limit the scope of payment, avoid abuse, promote rational use, control fund expenditure, and select the best drug delivery program The limitation of medical insurance is not medical behavior, but medical insurance payment behavior Therefore, when medical insurance pays, doctors should be required to provide reliable evidence of medical behavior The goal of the new catalogue is to improve the treatment of medical security, promote the progress of clinical medication and rational use of drugs, and guide the development of innovative drugs In the end, he also put forward the future prospects of the medical insurance drug Catalog: in terms of scope, adhere to the basic guarantee and gradually expand the catalog varieties; in terms of mechanism, improve the dynamic adjustment and improve the flexibility and maneuverability; in terms of method, emphasize expert review and attach importance to objective evidence; in terms of content, standardize the catalog arrangement and appropriately expand the functions; in terms of management, unify the technical standards and strengthen the drug administration.